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Background: This study explored the impact of genetic polymorphisms in cytochrome P450 (CYP) enzymes and
transporters on the plasma trough concentration of imatinib mesylate (IM) and clinical response in chronic myeloid
leukemia (CML).
Patients and methods: In total, 82 patients with CML who had been administered 400 mg IM daily for over 6
months were genotyped for 11 single-nucleotide polymorphisms in nine genes (CYP3A4, CYP3A5, CYP2C9,
CYP2C19, CYP2D6, ABCB1, SLC22A1, SLC22A2 and ABCG2) using blood samples. The trough imatinib
concentration and clinical responses were assessed 6 months after the initiation of IM therapy.
Results: The CC, CA and AA genotypes in ABCG2 421C>A gave signiﬁcantly different frequencies for the major
molecular response (MMR) (P = 0.02). However, no signiﬁcant differences were found between the genotypes of the
CYP enzymes and transporters identiﬁed in this study and the imatinib plasma trough concentrations and clinical
response frequencies, except for the correlation of ABCG2 with MMR.
Conclusions: The results of the present study may indicate that the ABCG 421C>A genetic polymorphism inﬂuences
the MMR of imatinib in patients with CML.
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introduction
Imatinib mesylate (IM), a selective tyrosine kinase inhibitor, is
prescribed to treat chronic myeloid leukemia (CML) and
gastrointestinal stromal tumors [1, 2]. IM has dramatically
improved the long-term survival rate and clinical response of
CML patients, but suboptimal response and response failure to
the treatment are also observed [3, 4]. Several mechanisms that
lead to IM resistance have been investigated, including the
suggestion that pharmacogenetic variability inﬂuences the
pharmacokinetics of IM [4, 5]. It is well known that IM
pharmacokinetics have an obvious correlation with the
cytogenetic and molecular responses of CML [6, 7]. It has also
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been suggested that genetic polymorphisms of cytochrome
P450 (CYP) enzymes and transporters inﬂuence the IM
pharmacokinetics leading to IM resistance.
IM is metabolized by the CYP system in the liver, in which
the isoenzymes CYP3A4 and CYP3A5 play a major role. Other
isoenzymes, including CYP1A2, CYP2D6, CYP2C9 and
CYP2C19, are also known to contribute to the metabolism of
IM, but to a relatively minor extent [8–12]. IM is a substrate
for the breast cancer resistance protein (BCRP) encoded by
ABCG2, the p-glycoprotein encoded by ABCB1 and the
organic cation transporter 1 encoded by SLC22A1 [13–19].
In this study, we investigated the inﬂuence of genetic
polymorphisms on the CYP enzymes and transporters linked
to the pharmacokinetics of IM using trough imatinib
concentration and clinical response in CML patients. We used
blood samples to perform genotyping and clinical information
from a previous study to evaluate the correlation of trough IM
concentration with the cytogenetic or molecular response in
Korean CML patients [20].
methods
subjects and study design
This study was carried out according to the declaration of Helsinki and the
International Conference on Harmonization-Good Clinical Practice
standards. The study protocol was approved by the local institutional
review boards, and all volunteers signed written informed consent after
receiving a full explanation of the study. In total, 100 patients with newly
diagnosed chronic phase CML were enrolled from 23 major hospitals in
Korea, and 82 patients were ﬁnally enrolled. These comprised 58 male and
24 female patients with a median age of 50 (range 17–79) years. Each
patient was orally administered 400 mg IM daily for at least 6 months. The
cytogenetic response, measured by bone marrow aspiration, was assessed at
diagnosis and after 6 months. The molecular response using peripheral
blood was assessed at diagnosis and then every 3 months. A complete
cytogenetic response (CCyR) was deﬁned as 0% of Philadelphia
chromosome-positive cells based on the full analysis of 20 metaphases of
bone marrow. A major molecular response (MMR) was deﬁned as a more
than three-log reduction in BCR-ABL transcripts compared with the
baseline value. CCyR was achieved in 63 patients (76.8%) and MMR in 13
(15.9%) at 6 months after treatment.
laboratory analysis
genotyping
DNA extraction from blood samples was carried out using a QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genotyping for the
CYP3A4*18 (878T>C), CYP3A5*3C (6986A>G), CYP2C9*3 (1075A>C),
CYP2C19*2 (681G>A), CYP2C19*3 (636G>A), CYP2D6*10B (100C>T),
ABCB1 1236C>T, ABCB1 3435C>T, SLC22A1 1022C>T, SLC22A2
808G>T and ABCG2 421C>A alleles was carried out using the TaqMan®
allelic discrimination assay (Applied Biosystems, Foster City, CA, USA)
[21]. The pre-developed TaqMan assay reagent kit (Applied Biosystems)
was used, and polymerase chain reaction (PCR) was carried out in 384-well
PCR plates using Real-Time PCR 7900H (ABI, USA) as per the standard
TaqMan allelic discrimination assay protocol provided by Applied
Biosystems. The Hardy–Weinberg equilibrium was conﬁrmed for all of the
analyzed single-nucleotide polymorphism (SNP) data.
plasma IM concentration and RQ-PCR
Blood sampling for trough plasma imatinib concentration was carried out
between 21 and 27 h after the last IM dosing. Plasma samples were
prepared and analyzed using high performance liquid chromatography–
mass spectrometry, following a method described previously [22].
The molecular response was assessed as the BCR–ABL/ABL log ratio
using real-time quantitative reverse transcriptase PCR (RQ-PCR) in the
single laboratory (ISU ABXIS Co., Ltd., Seoul), following a method
described previously [23]. Total RNA was extracted from the peripheral
blood samples, and the ratio of BCR–ABL fusion transcripts to ABL
transcripts was quantiﬁed. ABL was used as the control gene. The
standardized baseline value was determined as the median value of the
BCR–ABL/ABL level of 20 newly diagnosed chronic phase CML patients
before IM medication [24].
statistical analysis
Statistical differences of imatinib trough concentration between genotypes
of each SNP were determined using Kruskal–Wallis or Mann–Whitney
tests. Statistical differences of cytogenetic and molecular responses between
genotypes of each SNP were determined using Chi-square or Fisher’s exact
tests. P-values <0.05 were deemed to indicate statistical signiﬁcance.
results
genotype and imatinib concentration
Genotypes and allele frequencies for all genes evaluated in this
study are shown in Table 1. The Hardy–Weinberg equilibrium
test was conﬁrmed for all genotypes.
The comparisons of imatinib trough concentration with
enzyme and transporter genotypes are shown in Table 2. There
were no statistically signiﬁcant differences in the imatinib
trough concentration when comparing all enzyme and
transporter genotypes.
genotype and clinical response
A comparison of the cytogenetic response among enzyme and
transporter genotypes is summarized in Table 3. The
Table 1. Genotype and allele frequencies of the genes evaluated in this
study
Variant Genotype frequency Allele
frequency
Wild Hetero Variant P q
Enzyme genotype
CYP3A4*18 (878T>C) 77 (93.9) 5 (6.1) 0 (0) 0.970 0.030
CYP3A5*3C (6986A>G) 3 (3.7) 27 (32.9) 52 (63.4) 0.201 0.799
CYP2C9*3 (1075A>C) 77 (93.9) 5 (6.1) 0 (0) 0.970 0.030
CYP2C19*2 (681G>A) 42 (51.2) 37 (45.1) 3 (3.7) 0.738 0.262
CYP2C19*3 (636G>A) 65 (79.3) 17 (20.7) 0 (0) 0.896 0.104
CYP2D6*10B (100C>T) 24 (29.3) 35 (42.7) 23 (28.0) 0.506 0.494
Transporter genotype
ABCB1 1236C>T 17 (20.7) 37 (45.1) 28 (34.1) 0.433 0.567
ABCB1 3435C>T 35 (42.7) 38 (46.3) 9 (11.0) 0.659 0.341
SLC22A1 1022C>T 58 (70.7) 24 (29.3) 0 (0) 0.854 0.146
SLC22A2 808G>T 67 (81.7) 15 (18.3) 0 (0) 0.909 0.091
ABCG2 421C>A 41 (50.6) 32 (39.5) 8 (9.9) 0.704 0.296
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frequencies of CCyR and non-CCyR were compared between
genotypes using Chi-square or Fisher’s exact tests. There were
no statistically signiﬁcant differences in cytogenetic response
frequency for any enzyme or transporter genotype investigated
in this study.
A comparison of the molecular response among enzyme
and transporter genotypes is summarized in Table 4. The
frequencies of MMR and non-MMR were compared
between the genotypes using Chi-square or Fisher’s exact
tests. There were no statistically signiﬁcant differences in
the molecular response among any of the enzyme or
transporter genotypes investigated in this study, except for
ABCG2 421C>A.
In ABCG2 421C>A, the frequency of MMR was 5 of 41
patients with the CC genotype, 4 of 32 with the CA genotype
Table 2. Comparison of imatinib trough concentration with the enzyme
and transporter genotypes
Genotype n Imatinib trough
concentration (ng/ml)
P-value
Mean SD
Enzyme genotype
CYP3A4*18 (878T>C)
Wild 77 1348.8 715.6 0.71
Hetero 5 1330.4 339.3
CYP3A5*3C (6986A>G)
Wild 3 1366.7 526.9 0.50
Hetero 27 1386.8 538.6
Variant 52 1326.3 782.4
CYP2C9*3 (1075A>C)
Wild 77 1349.2 705.7 0.86
Hetero 5 1324.6 617.7
CYP2C19*2 (681G>A)
Wild 42 1428.4 602.7 0.18
Hetero 37 1265.2 809.6
Variant 3 1235.3 407.2
CYP2C19*3 (636G>A)
Wild 65 1315.6 692.2 0.41
Hetero 17 1470.5 724.4
CYP2D6*10B (100C>T)
Wild 24 1501.6 908.6 0.15
Hetero 35 1381.0 583.2
Variant 23 1136.4 572.0
Transporter genotype
ABCB1 1236C>T
Wild 17 1326.9 479.4 0.57
Hetero 37 1282.3 617.2
Variant 28 1446.7 893.4
ABCB1 3435C>T
Wild 35 1211.1 469.3 0.62
Hetero 38 1455.3 844.0
Variant 9 1424.7 741.0
ABCB1 haplotype
C–C 71 1303.6 65.2 0.52
C–T 37 1284.2 127.6
T–T 56 1445.4 106.8
SLC22A1 1022C>T
Wild 58 1374.0 606.8 0.23
Hetero 24 1284.0 890.9
SLC22A2 808G>T
Wild 67 1396.2 735.9 0.23
Hetero 15 1131.2 445.4
ABCG2 421C>A
Wild 41 1227.5 582.3 0.15
Hetero 32 1459.8 864.3
Variant 8 1563.4 404.1
Table 3. Comparison of cytogenetic response with the enzyme and
transporter genotypes
Genotype n CCyR Non-CCyR P-value
Enzyme genotype
CYP3A4*18 (878T>C)
Wild 77 59 18 1.00
Hetero 5 4 1
CYP3A5*3C (6986A>G)
Wild 3 2 1 0.64
Hetero 27 22 5
Variant 52 39 13
CYP2C9*3 (1075A>C)
Wild 77 59 18 1.00
Hetero 5 4 1
CYP2C19*2 (681G>A)
Wild 42 30 12 0.34
Hetero 37 31 6
Variant 3 2 1
CYP2C19*3 (636G>A)
Wild 65 48 17 0.21
Hetero 17 15 2
CYP2D6*10B (100C>T)
Wild 24 20 4 0.10
Hetero 35 29 6
Variant 23 14 9
Transporter genotype
ABCB1 1236C>T
Wild 17 15 2 0.13
Hetero 37 30 7
Variant 28 18 10
ABCB1 3435C>T
Wild 35 30 5 0.13
Hetero 38 28 10
Variant 9 5 4
ABCB1 haplotype
C–C 71 60 11 0.09
C–T 37 28 9
T–T 56 38 18
SLC22A1 1022C>T
Wild 58 43 15 0.37
Hetero 24 20 4
SLC22A2 808G>T
Wild 67 51 16 1.00
Hetero 15 12 3
ABCG2 421C>A
Wild 41 34 7 0.52
Hetero 32 23 9
Variant 8 6 2
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and 4 of 8 with the AA genotype (P = 0.02). The comparison
of CC + CA with AA genotypes was also signiﬁcantly different
(P = 0.02). The odds ratio of CC + CA over AA was 0.14 (95%
conﬁdence interval 0.03–0.66).
discussion
ABCG2 421C>A in exon 5 is a non-synonymous SNP, where a
glutamine is substituted with a lysine residue at codon 141
(Q141K). Our data suggest that the ABCG2 421 variant allele
is related to a higher rate of MMR in CML patients using
imatinib. Although there was no statistically signiﬁcant
difference in trough imatinib concentrations between the
ABCG2 421C>A genetic variants, the mean value was higher
in the group with more A variants. The mean trough imatinib
concentrations of the CC, CA and AA groups were
1227.5 ± 582.3, 1459.8 ± 864.3 and 1563.4 ± 404.1 ng/ml
(mean ± standard deviation [SD]), respectively (P = 0.15).
It has been reported that human embryonic kidney 293 cells
transfected with ABCG2 Q141K showed a higher imatinib
accumulation compared with wild-type ABCG2 in vitro [14].
In a further study, it was determined that dose-adjusted
imatinib trough concentrations were higher in patients with
the CA or AA genotype compared with the CC genotype in 67
Japanese CML patients [15]. In the same study, there was no
signiﬁcant correlation observed between clinical responses and
ABCG2 421 genetic variants [15]. However, the clinical
relevance of ABCG2 421C>A with imatinib was demonstrated
in a study of 229 Canadian CML patients [25]. In this study,
the AA genotype exhibited a higher MMR than the CA or CC
genotype.
The inﬂuence of ABCG2 421C>A on imatinib concentration
and clinical response is good agreement with this and other
previous reports, although some studies failed to determine the
effect of ABCG2 421C>A on the imatinib response.
Oral absorption of imatinib is rapid and almost complete;
the absolute bioavailability is >97% [26]. Imatinib is extensively
metabolized after absorption and excreted mainly through the
biliary route. The recovery of the administered dose in feces is
>70%, detected as imatinib or its metabolites [27]. In the
process of excretion, BCRP encoded by ABCG2 at the apical
membrane of hepatocytes may play a substantial role.
Therefore, the genetic variability of the ABCG2 gene may
inﬂuence the variability of the pharmacokinetics and clinical
response of imatinib.
In conclusion, this study showed that ABCG2 421C>A
genetic variation may inﬂuence the molecular response of
imatinib in CML patients. Although further studies are needed
to conﬁrm this result due to the non-conﬁrmative ABCG2
421C>A data and the complexity of other inﬂuencing factors,
ABCG2 421C>A genotyping may be used to predict the
clinical response and applied to the reﬁnement of the imatinib
dose in CML patients.
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